We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

Thermal Imaging Predicts Side Effect Severity in Head and Neck Cancer Patients

By HospiMedica International staff writers
Posted on 09 Feb 2012
Slight temperature increases of the oral mucus membranes early in a head and neck cancer patient’s chemotherapy and radiation therapy (chemoradiotherapy) treatment is a predictor of severe mucositis later in treatment.

These new findings were presented January 27, 2012, at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by the American Head and Neck Society (AHNS), American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Nuclear Medicine (SNM), held in Phoenix (AZ, USA).

Mucositis is a typical side effect of chemoradiotherapy for head and neck cancer that is painful and can be very severe. More...
Physicians cannot predict which patients will have mild mucositis or severe mucositis that would require narcotic pain medication, nutritional support, and/or feeding tubes.

The investigators theorized that using sensitive thermal imaging technology to gauge temperature alterations of less than one-tenth of a degree early in treatment could predict the severity of mucositis later in treatment. This information could allow for early intervention and potential changes in therapy using a technology that is simple, harmless, and noninvasive.

Patients receiving chemoradiotherapy underwent baseline and weekly thermal imaging of their oral mucus membranes. All patients displayed an increase in temperature and severe mucositis was found in 53% of patients. “If we could predict which patients were going to suffer the greatest toxicity, we could proactively make changes to their care that could ameliorate or prevent side effects,” concluded Ezra Cohen, MD, lead author of the study and codirector of the head and neck cancer program at the University of Chicago (IL, USA).

“Ultimately, we could identify the patients at higher risk of severe complications from treatment.”

Related Links:

University of Chicago




Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Patient Preoperative Skin Preparation
BD ChloraPrep
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.